Compare iShares MSCI India ETF (INDA) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI India ETF vs Summit Therapeutics Inc — how do they compare? iShares MSCI India ETF trades at $48.2, while Summit Therapeutics Inc trades at $14.68 (market cap $11.34B). The key difference: iShares MSCI India ETF is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| INDA | SMMT | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $55.29 | $29.32 |
52-Week Low | $45.42 | $13.05 |
Market Cap | — | $11.34B |
Enterprise Value | — | $10.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INDA, the iShares MSCI India ETF, trades at $48.56, down 0.72% on the day. The technical outlook is bearish, with moving averages indicating selling pressure and oscillators neutral. Recent news highlights India's strong economic growth at 7.8% for Q1 2026 (CNBC, 2026-06-05) but notes headwinds including muted IT sector performance and geopolitical risks from the Middle East.
The ETF offers exposure to India's fast-growing economy but faces near-term risks from sector-specific challenges and external volatility. Analyst sentiment is mixed, with some seeing value in the long-term growth story despite recent underperformance versus other emerging markets.
Summit Therapeutics (SMMT) trades at $13.50, down 2.24% on the day, reflecting a bearish technical trend amid negative profitability. The company reported a net loss of $1.08 billion for 2025, with deeply negative ROE and ROA, though a recent asset sale and positive clinical trial data for its oncology candidate provide some operational catalysts. Cash flow remains volatile, with net cash flow turning negative in 2026 projections.
The investment case is binary, hinging on the success of ivonescimab. While analyst consensus is bullish with a $15.57 price target, high volatility and ongoing fiduciary investigations pose significant risks. The stock offers high-reward potential for risk-tolerant investors betting on clinical success, but fundamental weaknesses and cash burn necessitate caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI India ETF
INDA tracks the MSCI India Index, providing broad exposure to large and mid-cap companies in the Indian stock market. It is structurally dominated by the financials, information technology, and energy sectors, serving as a core instrument for investors seeking a single-country view of India's long-term economic growth.
Read more on INDA →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
